References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34. doi: https://doi.org/10.3322/caac.21551.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: https://doi.org/10.3322/caac.21492.
- Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78–85. doi: https://doi.org/10.1056/NEJM200007133430201.
- Kasprzak A, Adamek A. Insulin-like growth factor 2 (IGF2) signaling in colorectal cancer-from basic research to potential clinical applications. Int J Mol Sci. 2019; 20(19):4915. doi: https://doi.org/10.3390/ijms20194915.
- Tie J, Cohen JD, Wang Y, Christie M, Simons K, Lee M, Wong R, Kosmider S, Ananda S, McKendrick J, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 2019; 5(12):1710–1717. doi: https://doi.org/10.1001/jamaoncol.2019.3616.
- Yuan W, Peng S, Wang J, Wei C, Ye Z, Wang Y, Wang M, Xu H, Jiang S, Sun D, et al. Identification and characterization of circRNAs as competing endogenous RNAs for miRNA–mRNA in colorectal cancer. PeerJ. 2019;7:e7602. doi: https://doi.org/10.7717/peerj.7602.
- Gao P, He M, Zhang C, Geng C. Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene. 2018;654:95–102. doi: https://doi.org/10.1016/j.gene.2018.02.007.
- Vlachavas EI, Pilalis E, Papadodima O, Koczan D, Willis S, Klippel S, Cheng C, Pan L, Sachpekidis C, Pintzas A, et al. Radiogenomic analysis of F-18-fluorodeoxyglucose positron emission tomography and gene expression data elucidates the epidemiological complexity of colorectal cancer landscape. Comput Struct Biotechnol J. 2019;17:177–185. doi: https://doi.org/10.1016/j.csbj.2019.01.007.
- Chen Z, Lin Y, Gao J, Lin S, Zheng Y, Liu Y, Chen SQ. Identification of key candidate genes for colorectal cancer by bioinformatics analysis. Oncol Lett. 2019;18(6):6583–6593. doi: https://doi.org/10.3892/ol.2019.10996.
- Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi: https://doi.org/10.1038/nprot.2008.211.
- Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi: https://doi.org/10.1093/nar/gkn923.
- Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(D1):D362–D368. doi: https://doi.org/10.1093/nar/gkw937.
- Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2. doi: https://doi.org/10.1186/1471-2105-4-2.
- Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK, Varambally S. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi: https://doi.org/10.1016/j.neo.2017.05.002.
- Zhang GL, Pan LL, Huang T, Wang JH. The transcriptome difference between colorectal tumor and normal tissues revealed by single-cell sequencing. J Cancer. 2019;10(23):5883–5890. doi: https://doi.org/10.7150/jca.32267.
- Hong BS, Cho JH, Kim H, Choi EJ, Rho S, Kim J, Kim JH, Choi DS, Kim YK, Hwang D, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics. 2009;10:556. doi: https://doi.org/10.1186/1471-2164-10-556.
- Smith FM, Stephens RB, Kennedy MJ, Reynolds JV. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer. 2005;92(9):1813. doi: https://doi.org/10.1038/sj.bjc.6602589.
- Jansson EA, Are A, Greicius G, Kuo IC, Kelly D, Arulampalam V, Pettersson S. The Wnt/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells. Proc Natl Acad Sci USA. 2005;102(5):1460–1465. doi: https://doi.org/10.1073/pnas.0405928102.
- Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, et al. β-Catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18(6):892–901. doi: https://doi.org/10.1038/nm.2772.
- Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–128. doi: https://doi.org/10.1038/nrgastro. 2017.119.
- Zhu C, Wang Y, Cai C, Cai Q. Bacterial infection and associated cancers. Adv Exp Med Biol. 2017;1018:181–191. doi: https://doi.org/10.1007/978-981-10-5765-6_11.
- Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002; 296(5571):1313–1316. doi: https://doi.org/10.1126/science.1070477.
- Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992;11(3):961–971.
- Yam CH, Fung TK, Poon RY. Cyclin A in cell cycle control and cancer. Cell Mol Life Sci. 2002;59(8):1317–1326. doi: https://doi.org/10.1007/s00018-002-8510-y.
- Kanai M, Shiozawa T, Xin L, Nikaido T, Fujii S. Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. Cancer. 1998;82(9):1709–1719. doi: https://doi.org/10.1002/(sici)1097-0142(19980501)82:9 < 1709::aid-cncr18 > 3.0.co;2-8.
- Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer. 2001;93(2):283–287. doi: https://doi.org/10.1002/ijc.1311.
- Volm M, Koomägi R. Relevance of proliferative and pro-apoptotic factors in non-small-cell lung cancer for patient survival. Br J Cancer. 2000;82(10):1747–1754. doi: https://doi.org/10.1054/bjoc.1999.1210.
- Brien TP, Depowski PL, Sheehan CE, Ross JS, McKenna BJ. Prognostic factors in gastric cancer. Mod Pathol. 1998;11(9):870–877.
- Ohashi R, Gao C, Miyazaki M, Hamazaki K, Tsuji T, Inoue Y, Uemura T, Hirai R, Shimizu N, Namba M. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res. 2001;21(1B):657–662.
- Liu D, Matzuk MM, Sung WK, Guo Q, Wang P, Wolgemuth DJ. Cyclin A1 is required for meiosis in the male mouse. Nat Genet. 1998;20(4):377–380. doi: https://doi.org/10.1038/3855.
- Murphy M, Stinnakre MG, Senamaud-Beaufort C, Winston NJ, Sweeney C, Kubelka M, Carrington M, Bréchot C, Sobczak-Thépot J. Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet. 1997;15(1):83–86. doi: https://doi.org/10.1038/ng0197-83.
- Li X, Ma XL, Tian FJ, Wu F, Zhang J, Zeng WH, Lin Y, Zhang Y. Downregulation of CCNA2 disturbs trophoblast migration, proliferation, and apoptosis during the pathogenesis of recurrent miscarriage. Am J Reprod Immunol. 2019;82(1):e13144. doi: https://doi.org/10.1111/aji.13144.
- Gan Y, Li Y, Li T, Shu G, Yin G. CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res. 2018;10:5113–5124. doi: https://doi.org/10.2147/CMAR.S176833.
- Brcic L, Heidinger M, Sever AZ, Zacharias M, Jakopovic M, Fediuk M, Maier A, Quehenberger F, Seiwerth S, Popper H. Prognostic value of cyclin A2 and B1 expression in lung carcinoids. Pathology. 2019;51(5):481–486. doi: https://doi.org/10.1016/j.pathol.2019.03.011.
- Brandeis M, Rosewell I, Carrington M, Crompton T, Jacobs MA, Kirk J, Gannon J, Hunt T. Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci USA. 1998;95(8):4344–4349. doi: https://doi.org/10.1073/pnas.95.8.4344.
- Strauss B, Harrison A, Coelho PA, Yata K, Zernicka-Goetz M, Pines J. Cyclin B1 is essential for mitosis in mouse embryos, and its nuclear export sets the time for mitosis. J Cell Biol. 2018;217(1):179–193. doi: https://doi.org/10.1083/jcb.201612147.
- Begnami MD, Fregnani JH, Nonogaki S, Soares FA. Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication. Hum Pathol. 2010;41(8):1120–1127. doi: https://doi.org/10.1016/j.humpath.2010.01.007.
- Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60(15):4000–4004.
- Niméus-Malmström E, Koliadi A, Ahlin C, Holmqvist M, Holmberg L, Amini RM, Jirström K, Wärnberg F, Blomqvist C, Fernö M, et al. Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort. Int J Cancer. 2010;127(4):961–967. doi:https://doi.org/10.1002/ijc.25091
- Murakami H, Furihata M, Ohtsuki Y, Ogoshi S. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch. 1999;434(2):153–158. doi: https://doi.org/10.1007/s004280050319.
- Weng L, Du J, Zhou Q, Cheng B, Li J, Zhang D, Ling C. Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection. Mol Cancer. 2012;11:39. doi: https://doi.org/10.1186/1476-4598-11-39.
- Xiao Z, Xue J, Gu WZ, Bui M, Li G, Tao ZF, Lin NH, Sowin TJ, Zhang H. Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors. Biomarkers. 2008;13(6):579–596. doi: https://doi.org/10.1080/13547500802063240.
- Fang Y, Liang X, Jiang W, Li J, Xu J, Cai X. Cyclin b1 suppresses colorectal cancer invasion and metastasis by regulating e-cadherin. PLoS One. 2015;10(5):e0126875. doi: https://doi.org/10.1371/journal.pone.0126875.
- Fang Y, Yu H, Liang X, Xu J, Cai X. Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer. Cancer Biol Ther. 2014;15(9):1268–1279. doi: https://doi.org/10.4161/cbt.29691.
- Yamamoto S, Takayama KI, Obinata D, Fujiwara K, Ashikari D, Takahashi S, Inoue S. Identification of new octamer transcription factor 1-target genes upregulated in castration-resistant prostate cancer. Cancer Sci. 2019;110(11):3476–3485. doi: https://doi.org/10.1111/cas.14183.
- Branchi V, García SA, Radhakrishnan P, Győrffy B, Hissa B, Schneider M, Reißfelder C, Schölch S. Prognostic value of DLGAP5 in colorectal cancer. Int J Colorectal Dis. 2019;34(8):1455–1465. doi: https://doi.org/10.1007/s00384-019-03339-6.
- Batra J, Robinson J, Soares AS, Fields AP, Radisky DC, Radisky ES. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem. 2012;287(19):15935–15946. doi: https://doi.org/10.1074/jbc.M112.341156.
- Wang YY, Li L, Zhao ZS, Wang HJ. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol. 2013;11:81. doi: https://doi.org/10.1186/1477-7819-11-81.
- Peng L, Yanjiao M, Ai-Guo W, Pengtao G, Jianhua L, Ju Y, Hongsheng O, Xichen Z. A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells. Biochem Biophys Res Commun. 2011;409(2):344–349. doi: https://doi.org/10.1016/j.bbrc.2011.05.021.
- Grunnet M, Mau-Sørensen M, Brünner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol. 2013;48(8):899–905. doi: https://doi.org/10.3109/00365521.2013.812235.
- Dechaphunkul A, Phukaoloun M, Kanjanapradit K, Graham K, Ghosh S, Santos C, Mackey JR. Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer. Int J Breast Cancer. 2012;2012:290854. doi: https://doi.org/10.1155/2012/290854.
- Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T, Wu L, Zhang T, Sun X, Zhong L, et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res. 2016;35(1):148. doi: https://doi.org/10.1186/s13046-016-0427-7.
- Yang L, Jiang Q, Li DZ, Zhou X, Yu DS, Zhong J. TIMP1 mRNA in tumor-educated platelets is diagnostic biomarker for colorectal cancer. Aging (Albany NY). 2019;11(20):8998–9012. doi: https://doi.org/10.18632/aging.102366.